about
Emerging and exotic zoonotic disease preparedness and response in the United States - coordination of the animal health component.Prospects for control of emerging infectious diseases with plasmid DNA vaccines.Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization.Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.Polymeric Materials for Gene Delivery and DNA VaccinationThe dichotomy of pathogens and allergens in vaccination approachesThe porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccineIntranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses.Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenzaAdjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGunPolyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responsesImmunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45Optimization and delivery of plasmid DNA for vaccination.Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines.The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells.Progress in the development of genetic immunization.The strategic use of novel smallpox vaccines in the post-eradication world.Preparation and immunological effectiveness of a Swine influenza DNA vaccine encapsulated in PLGA microspheres.Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses.A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.Purification of supercoiled plasmid DNA from clarified bacterial lysate by arginine-affinity chromatography: effects of spacer arms and ligand density.
P2860
Q30223257-2EDE821A-E368-4DB1-B2DB-26A62A412ACAQ30380454-C8A9FF30-4655-4B40-9D7C-AA16BFF1BE39Q30423733-86E6A6EA-C38E-442C-9809-81EB5056FA2EQ30437330-3CD2AD97-2034-40FE-8473-EB5B3A399430Q33346277-1B63D46E-CDEA-4E4C-B55B-222F44BA88BFQ33565296-ECC21D24-3378-4229-867D-5E90ED009CE8Q33909251-0597F873-5168-4552-BB69-48C9E4E90B46Q34586248-ED991FB8-01DE-4771-A113-3B227B6CAE27Q34621661-5D74405D-F229-4A3D-BE96-3C72547371EFQ35023393-63E3696B-3FAD-44B2-B926-5235E57CF640Q35066456-A06EE3DD-8ED4-4487-9476-47727B2715B2Q35339702-BAD4D3F2-49C7-4FA5-8237-DB36A13BDDA6Q36256348-7162EEB3-1FCE-4BDC-B189-5FE56F35D902Q36256428-BD43BA64-CB61-4983-9C69-032724997314Q36690285-9896F24F-34E0-47C7-820C-BEFBF423988BQ37127370-7265BB1D-2CFF-4B59-B6B8-F66283622FC3Q37155956-783A78D4-C6CD-47FC-B7E5-3D14EB7AD6B6Q37316018-D1431916-91AD-4FE4-A1F9-42BB89454863Q37909421-AE10C9FF-80E4-4126-B331-B54570F48286Q39745470-107CE844-9D51-4CD9-83A7-2EDE80A80096Q41035371-95D1ED91-8B2C-4816-AC21-97C4D4644AB9Q44341358-598168D8-F059-4DF9-8A58-A2D2D5B696C1Q47890332-F7ED7774-03AF-4B5F-A963-FCD452606E84
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Rapid-response vaccines--does DNA offer a solution?
@en
type
label
Rapid-response vaccines--does DNA offer a solution?
@en
prefLabel
Rapid-response vaccines--does DNA offer a solution?
@en
P2860
P356
P1433
P1476
Rapid-response vaccines--does DNA offer a solution?
@en
P2093
Gareth M Forde
P2860
P2888
P304
P356
10.1038/NBT0905-1059
P577
2005-09-01T00:00:00Z